Objective: To evaluate the effect of hydroethanolic extract of yacon on the hyperglycemia induced by streptozotocin (STZ) in neonatal rats. Methods: Wistar rats aged two days old received an intraperitoneal injection of STZ (160 mg/kg); after seven weeks, glycosuria was determined and animals with glucose levels above 250 mg/dL were included in the study. Groups of diabetic and non-diabetic rats were treated orally with yacon extract at a dose of 400 mg/kg/d for 14 d. Tests were made for phytochemical characterization, glucose tolerance and toxicity. Results: The results showed that treatment with the extract reduced the glucose levels of fed diabetic rats and did not change the glucose levels of fasting diabetic and normal rats. Additionally, also it was observed that treatment with the extract reduced blood glucose levels of diabetic rats during the oral and intravenous glucose tolerance tests. There was no change in body weight, liver enzymes or mortality with yacon extract treatment. The phytochemical screening revealed the presence of caffeic acid, chlorogenic acid, ferulic acid and gallic acid. Conclusions: The data suggest that yacon extract reduces hyperglycemia, possibly by improving insulin sensibility through its phytochemicals constituents (phenolic compounds).
Introduction
Diabetes mellitus is a serious chronic disease, and is considered one of the five leading causes of death worldwide [1, 2] . This disease is characterized by high blood glucose levels, caused by a deficiency in insulin secretion and/or a resistance to insulin action [3] .
Diabetes mellitus can be classified as diabetes mellitus type 1 (DM1) and diabetes mellitus type 2 (DM2). DM1 is characterized by an absolute deficiency of insulin secretion associated with the autoimmune destruction of pancreatic b cells. DM2, which accounts for over 90% of cases, is caused by a combination of resistance to insulin action and impaired secretion of this hormone [4] . In DM2, muscle and adipose tissue are resistant to insulin and compensatory insulin secretion is insufficient to maintain the physiological levels of glucose [5] .
Drug therapy for diabetes is conventionally performed using oral hypoglycemic agents (such as metformin, glyburide, chlorpropamide, and others) and insulin. However, based on recommendations of the World Health Organization [6] , antidiabetic agents derived from plants are an important alternative for the treatment of disease. In recent years, interest in using natural products for pharmacological purposes has increased greatly as a form of complementary therapy. Particularly in the case of diabetes, studies have shown that plant extracts are effective in reducing blood glucose, causing fewer adverse effects compared to traditional anti-diabetic agents [7, 8] .
The yacon plant is native of the Andes, the family Asteraceae (Compositae), the species Smallanthus sonchifolius (S. sonchifolius). Aybar et al. [9] demonstrated the antihyperglycemic effect of aqueous extracts obtained from leaves of yacon in normoglycemic rats, transiently hyperglycemic by glucose tolerance or diabetic. Recent studies by our group showed that treatment with extracts of yacon for 14 d reduced blood glucose levels in diabetic animals (DM1) and that this effect was not related to reduced food intake or interference of the extract on the intestinal absorption of carbohydrates [10] . In addition, other studies have shown that the butanol, chloroform and methanol fractions of yacon leaves extracts also reduced the blood glucose of diabetic rats [11] . The aim of this study was to evaluate whether the hydroethanolic extract of yacon changes the hyperglycemia induced by streptozotocin (STZ) in neonatal rats.
Material and methods

Preparation of hydroethanolic extract of yacon
The extracts were prepared from S. sonchifolius leaves acquired from Takashi Kakihara Ltda., Capão Bonito -São Paulo, Brazil. A voucher specimen was deposited at the Herbarium of the State University of Maringá under number HUEM 13021. Hydroethanolic extract from S. sonchifolius was obtained from 10% (w/w) solution with 70% ethanol, stirred mechanically for 5 h. Next, the extract was filtered, slowly evaporated to remove the solvent, lyophilized, and stored at −20 C. For the assays, the hydroethanolic extract of S. sonchifolius (hydroethanolic extract of yacon) was suspended in water immediately before use.
Chromatographic procedures
The hydroethanolic extract of yacon was fractionated by means of high performance liquid chromatography (HPLC). The HPLC system (Shimadzu ® , Japan) consisted of a system controller (SCL-10AVP), two pumps (model LC10ADVP), a column oven (model CTO-10AVP), and a UV-vis detector (model SPD-10AVP). A reversed-phase column C18HRC-ODS (Shimadzu ® , Japan), protected with a pre-column GHRC-ODS (Shimadzu ® , Japan), was used. The injection volume was 20 ml.
The mobile phase was methanol/acetic acid 4% (3/7), with the flow 1 ml/min and temperature of 35 C. Spectrophotometric monitoring was performed at 254 nm. The identification of each compound was based on a comparison of the retention time of external standards.
Induction of diabetes
Diabetes was induced in male newborn (2 d old) Wistar rats injected intraperitoneally with STZ (160 mg/kg) dissolved in citrate buffer (10 mM; pH 4.5). The animals were maintained at a controlled temperature (±22 C) and a 12-h-dark-light cycle, with balanced food and free access to water. The protocol for these experiments was approved by the Committee on Experimental Animal Ethics of the State University of Maringá. Seven weeks later, the diabetic state was confirmed by urine glucose level determination and animals with glycosuria above 250 mg/dL were included in the study.
Treatment of diabetic and normal rats
The hydroethanolic extract of yacon (400 mg/kg body weight) or water was administered by the oral route (gavage), in a single daily dose, in diabetic and normal rats for 14 d. The body weights of rats were evaluated daily, during experimental period.
Effect of hydroethanolic extract of yacon on glycemia and the activity of plasma phosphatase and transaminases
Blood samples were collected from the inferior vena cava blood in heparinized tubes, and centrifuged at 1 100 ×g for 15 min, and the plasma was separated. The concentration of glucose was determined in aliquots of plasma (10 ml), using the glucose oxidase colorimetric enzymatic method (Gold Analisa ® ). The activity of alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) was determined in the plasma of diabetic and normal rats, by the colorimetric-kinetic method, using a commercial kit (Gold Analisa ® ).
Oral glucose tolerance test (OGTT)
After 14 d of treatment with the hydroethanolic extract of yacon, the animals under fasting for 15 h received an oral glucose solution (1 g of 50% glucose solution/kg body weight). At zero, 15 and 30 min after the administration of glucose solution, blood samples were collected from the tails of animals to determine the concentration of plasma glucose using the glucose oxidase colorimetric enzymatic method (Gold Analisa ® ).
Intravenous glucose tolerance test (EGTT)
After 14 d of treatment with the hydroethanolic extract of yacon, the animals under fasting for 15 h received intravenous glucose solution (0.5 g of 50% glucose solution/kg body weight). At zero, 5, 10, 20, 30 and 60 min after glucose infusion, blood samples were collected from the inferior vena cava of the animals and conditioned in heparinized tubes. The plasma glucose concentration was determined by glucose oxidase colorimetric enzymatic method (Gold Analisa ® ).
Statistical analysis
The statistical analysis of the data was done using GraphPad Prism ® (GraphPad Software Inc., Microsoft Corp.). Results were expressed as mean ± standard error of the mean and analyzed using analysis of variance (ANOVA followed by Tukey's test) for multiple comparisons. The area under the curve was calculated using the trapezoidal rule. P < 0.05 was considered the criterion for significance.
Results
Chemical constituents of hydroethanolic extract of yacon
The HPLC method using a C18 column was commonly used to assess the presence of polyphenols in plant extracts. Four phenolic acids were identified by comparing the retention time of external standards: caffeic acid, chlorogenic acid, ferulic acid and gallic acid (Figure 1 ).
Effect of hydroethanolic extract of yacon on glycemia in diabetic and normal rats
The effect of yacon on glycemia in diabetic and normal rats in the fed state and in fasting state is shown in Figure 2A and Figure 3A , and these results are demonstrated by area under the curve in Figure 3B. Figure 4A and B shows changes in plasma glucose levels during ETTG in diabetic and normal rats under fasting. In normal rats, glucose levels were significantly increased 5 min after the glucose load and gradually reduced over the 60 min experiment 
Effect of hydroethanolic extract of yacon on transient hyperglycemia induced by intravenous administration of glucose (ETTG)
Effect of hydroethanolic extract of yacon on body weight and liver injury of diabetic and normal rats
The treatment of diabetic and normal animals with yacon extract did not change the body weight, without any significant differences between groups (data not shown). Additionally, the activity of liver enzymes (AST, ALT and ALP) was not significantly increased in the plasma of diabetic and normal rats treated with yacon extract (Table 1) . Mortality was not observed in the treated groups (data not shown).
Discussion
Ethnobotanical studies show that around 800 plants are used as traditional remedies for the treatment of diabetes due to their effectiveness, fewer side effects and relatively lower cost [12] ; in this context, the use of leaves and/or yacon roots has shown antihyperglycemic activity [13, 14] .
Baroni et al. [10] found that the crude extract of yacon leaves significantly reduced blood glucose levels of diabetic rats in the experimental model induced by STZ. It was also shown that the hydroethanolic fraction of the extract was able to reduce the glycogen content of the liver and skeletal muscle, and restored the activity of glucose 6-phosphate dehydrogenase in type 1 diabetic rats [13] . Additionally, Genta et al. [11] also showed that the methanolic, butanolic and chloroform yacon extract, tested in a type 1 diabetes model induced by STZ, increased the plasma levels of insulin, reducing the blood glucose. However, the above results are associated with a fasting state in experimental models of DM1, which is different to the results of the present study in which the effect of the hydroethanolic yacon extract was observed in the fed state in a newborn STZ-diabetes model. This experimental model has been widely used as a tool for the research of compounds with anti-diabetic actions, as well as to study the mechanism involved in disease, as it exhibits several phases of DM2, such as impaired glucose tolerance, and mild, moderate or severe glycemia. It has been reported that blood glucose changes and chronic hyperglycemia develop in rats that receive STZ injection on the second day after birth [15] [16] [17] [18] .
The results of this study demonstrated that the hydroethanolic extract of yacon (400 mg/kg) significantly (P < 0.05) reduced blood glucose level in fed diabetics rats when compared with the control rats (normal). To confirm this anti-hyperglycemic effect, oral and intravenous glucose tolerance tests were conducted, which can identify insulin sensitivity [8] . Yacon reduced the blood glucose levels of diabetic rats after glucose loading in both tests, but did not change the glucose levels in normal rats. These results are possibly due to the reduction of insulin resistance. An insulin-resistant state is one of the biggest risk factors for developing diabetes [19] ; therefore, reducing insulin resistance can positively contribute to the control of diabetes mellitus complications.
The improvement of glycemia using the hydroethanolic extract of yacon may be due to its phytochemical constitution. Genta et al. [11] showed that the hypoglycemic effect of butanolic yacon extract was attributed to the presence of phenolic compounds such as caffeic acid and chlorogenic acid. Other authors have also shown that plants rich in phenolic compounds, flavonoids, terpenoids and coumarin have potential hypoglycemic effects [20] [21] [22] [23] . Among these compounds, caffeic acid in particular is associated with reduced blood glucose [24] and chlorogenic acid to recover glucose intolerance and insulin resistance [25] . Additionally, it was also shown that the gallic acid increases plasma insulin [26] . Our results showed that the phytochemical analysis of the hydroethanolic extract yacon identified the presence of phenolic compounds such as caffeic acid, ferulic acid, gallic acid and chlorogenic acid, which may possibly contribute to the anti-hyperglycemic effect observed.
Interestingly, treatment with hydroalcoholic extract of yacon for 14 d (400 mg/kg/d) did not cause liver damage and mortality, and also did not affect the weight gain of animals. The nontoxicity effect was also observed in the study by Oliveira et al. [27] , who showed that polar yacon extract (rich in phenolic compounds such as chlorogenic acid, caffeic acid and coumarin compounds) produced toxicity only at high doses (1 000 mg/kg) following prolonged treatment (90 d). The authors suggest that the polar extract is safe for oral administration since it presents low or absent sesquiterpene lactones.
Among the strategies for diabetes control are normalization of glucose-induced insulin secretion and restoring glucose transport into insulin sensitive tissues. Our results showed that the hydroethanolic extract of yacon has the potential ability to control hyperglycemia probably through one or a combination of the above mechanisms. However, further work should be carried out to determine the toxicity profile, isolate the bioactive compound(s) in the plant and determine the exact mechanism(s) of action. 
